Department of Internal Medicine, University of Antioquia, Medellín, Colombia.
Department of Hematology, University of Antioquia, Medellín, Colombia.
Am J Case Rep. 2021 Feb 17;22:e929401. doi: 10.12659/AJCR.929401.
BACKGROUND Acquired hemophilia is a bleeding disorder mediated by an autoimmune process, in which antibodies against clotting factors are developed. This is a rarely suspected complex condition in which the initial manifestations are spontaneous bleeding in the skin, soft tissues, and mucosa in patients with no known history of bleeding disorders. Most of the cases are idiopathic (50%), but it can be associated with autoimmune diseases, malignancy, pregnancy, and medications. The most frequent type is mediated by inhibitors against factor VIII, followed by coagulation factor IX and XI. It is a disease with high morbidity and mortality rates without adequate treatment. Diagnosis is based on the detection of low concentrations of clotting factors and the presence of an inhibitor. CASE REPORT We present 2 cases of patients with spontaneous bleeding in whom the diagnosis of idiopathic acquired hemophilia A was made, an extensive malignancy study was performed that was negative, and the presence of autoimmunity markers (positive antinuclear antibodies (ANA)) was observed, without any another sign of autoimmune disease. They received immunosuppressive therapy with bleeding control and inhibitor eradication. CONCLUSIONS Acquired hemophilia A is a rare but potentially lethal disease, representing a medical challenge from its diagnosis to its treatment. An early recognition and treatment are fundamental because delays are associated with adverse outcomes. Optimal management includes the workup and treatment for an underlying disease, use of "bypass" agents when active bleeding presents, and inhibitor titer eradication through immunosuppressants drugs. With the present cases, we highlight the importance of considering acquired hemophilia A in older patients with similar symptoms, to achieve early diagnosis and treatment.
获得性血友病是一种由自身免疫过程介导的出血性疾病,在此过程中会产生针对凝血因子的抗体。这是一种很少被怀疑的复杂疾病,其最初表现为无已知出血性疾病史的患者皮肤、软组织和黏膜自发性出血。大多数病例为特发性(50%),但也可与自身免疫性疾病、恶性肿瘤、妊娠和药物有关。最常见的类型是由针对凝血因子 VIII 的抑制剂介导的,其次是凝血因子 IX 和 XI。如果没有适当的治疗,这种疾病的发病率和死亡率都很高。诊断基于检测凝血因子浓度降低和存在抑制剂。病例报告:我们报告了 2 例自发性出血患者,诊断为特发性获得性血友病 A,进行了广泛的恶性肿瘤研究,结果为阴性,并观察到自身免疫标志物(阳性抗核抗体(ANA))的存在,无任何其他自身免疫性疾病的迹象。他们接受了免疫抑制治疗,以控制出血和消除抑制剂。结论:获得性血友病 A 是一种罕见但潜在致命的疾病,从诊断到治疗都极具挑战性。早期识别和治疗至关重要,因为延迟会导致不良后果。最佳治疗包括对潜在疾病进行检查和治疗,在出现活动性出血时使用“旁路”药物,以及通过免疫抑制剂药物消除抑制剂滴度。通过本病例,我们强调了在具有类似症状的老年患者中考虑获得性血友病 A 的重要性,以实现早期诊断和治疗。